Biocon Limited has informed the Exchange regarding a press release dated August 31, 2020, titled "Biocon Biologics and Mylan Announce Launch of Semglee (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes.".
Biocon Limited has informed the Exchange regarding a press release dated August 31, 2020, titled "Biocon Biologics and Mylan Announce Launch of Semglee (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes.".